Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2017 Apr;5(4):E275-E281.
doi: 10.1055/s-0043-101695.

International multicenter comparative trial of endoscopic ultrasonography-guided gastroenterostomy versus surgical gastrojejunostomy for the treatment of malignant gastric outlet obstruction

Affiliations

International multicenter comparative trial of endoscopic ultrasonography-guided gastroenterostomy versus surgical gastrojejunostomy for the treatment of malignant gastric outlet obstruction

Mouen A Khashab et al. Endosc Int Open. 2017 Apr.

Abstract

Background and study aims EUS-guided gastroenterostomy (EUS-GE) is a novel procedure that potentially offers long-lasting luminal patency without the risk of tumor ingrowth/overgrowth. This study compared the clinical success, technical success, adverse events (AEs), length of hospital stay (LOHS) and symptom recurrence in EUS-GE versus SGJ. Methods This was a multicenter international retrospective comparative study of EUS-GE and SGJ in patients with malignant gastric outlet obstruction (GOO) who underwent either EUS-GE or SGJ. EUS-GE was performed using lumen apposing metal stents. Results A total of 93 patients with malignant GOO treated with either EUS-GE (n = 30) or SGJ (n = 63) were identified. Peritoneal carcinomatosis was present in 13 (43 %) patients in the EUS-GE group and 7 (11 %) patients in the SGJ group (P < 0.001). Although the technical success rate was significantly higher in the SGJ group as compared to the EUS-GE group (100 % vs. 87 %, P = 0.009), the clinical success rate was not different (90 % vs. 87 %, P = 0.18, OR 0.8, 95 %CI 0.44 - 7.07). The rate of AEs was lower in the EUS-GE group, but the difference was not statistically significant (16 % vs 25 %, P = 0.3). The mean LOHS was similar in the EUS-GE group compared to SGJ (P = 0.35). The rate of recurrent GOO was not different between the two groups (3 % vs. 14 %, P = 0.08). Similarly, the mean time to reintervention was similar (88 days vs. 121 days, P = 0.83). Conclusions EUS-GE is associated with equivalent efficacy and safety as compared to surgical GJ. This is the first comparative trial between both techniques and suggests EUS-GE as a non-inferior but less invasive alter to surgery.

PubMed Disclaimer

Conflict of interest statement

Competing interests Mouen Khashab is a consultant for Boston Scientific. Todd Baron is a consultant for Boston Scientific. Jose Nieto is a consultant for Boston Scientific. Takao Itoi is a consultant for Boston Scientific

Figures

Fig. 1
Fig. 1
EUS-guided gastrojejunostomy using the direct puncture technique. a The small bowel is filled with fluid (saline, contrast and methylene blue) and is easily visualized transgastrically with EUS. It is first punctured with a 19-gauge fine-needle aspiration needle under EUS guidance with aspiration of blue-tinged fluid. Needle is removed and then the loop is directly accessed using the lumen apposing stent system. b The distal anchor flange is deployed first under EUS guidance followed by c deployment of the proximal flange under either endoscopic or sonographic guidance. c Stent is dilated with a balloon to 15 mm under endoscopic and fluoroscopic guidance. e The jejunum can be seen from within the deployed stent. f Contrast material is injected and confirms absence of leakage.
Fig. 2
Fig. 2
Kaplan Meier plot estimates the overall survival for patients undergoing EUS-GE vs SGJ. EUS-GE: Median survival 103 days with 95 % CI 45 – 160. SGJ: Median survival 148 days with 95 % CI 100 – 195. Median overall survival for the entire cohort is 130 days with 95 % CI 97 – 162. There was a significant difference in survival times between the 2 groups (P = 0.02 using Tarone-Ware; P = 0.006 using log rank)

References

    1. van Heek N T, van Geenen R C, Busch O R et al.Palliative treatment in “peri”-pancreatic carcinoma: stenting or surgical therapy? Acta Gastro-enterologica Belgica. 2002;65:171–175. - PubMed
    1. van Hooft J E, Uitdehaag M J, Bruno M J et al.Efficacy and safety of the new WallFlex enteral stent in palliative treatment of malignant gastric outlet obstruction (DUOFLEX study): a prospective multicenter study. Gastrointest Endosc. 2009;69:1059–1066. - PubMed
    1. Johnsson E, Thune A, Liedman B. Palliation of malignant gastroduodenal obstruction with open surgical bypass or endoscopic stenting: clinical outcome and health economic evaluation. World J Surgery. 2004;28:812–817. - PubMed
    1. Mehta S, Hindmarsh A, Cheong E et al.Prospective randomized trial of laparoscopic gastrojejunostomy versus duodenal stenting for malignant gastric outflow obstruction. Surg Endosc. 2006;20:239–242. - PubMed
    1. Fiori E, Lamazza A, Volpino P et al.Palliative management of malignant antro-pyloric strictures. Gastroenterostomy vs. endoscopic stenting. A randomized prospective trial. Anticancer Res. 2004;24:269–271. - PubMed